U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07812805) titled 'SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors' on Aug. 25.
Brief Summary: This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors. SKL35502 is an imaging agent used with SPECT scans to identify tumors with neurotensin receptor 1 (NTSR1), a protein found on some cancer cells, and to assess where the agent travels in the body and the radiation dose delivered to tissues. Participants with sufficient SKL35502 tumor uptake may receive SKL35501, a treatment designed to deliver targeted alpha radiation to NTSR1-ex...